胺碘酮相关性甲亢。

Amiodarone-induced thyrotoxicosis.

机构信息

Service endocrinologie, AP-HP, hôpital Cochin, 75014 Paris, France.

Service endocrinologie, AP-HP, hôpital Cochin, 75014 Paris, France; Université de Paris, 75014 Paris, France; Institut Cochin, Inserm Unité 1016, CNRS UMR 8104, 75014 Paris, France.

出版信息

Ann Endocrinol (Paris). 2021 Jun;82(3-4):163-166. doi: 10.1016/j.ando.2020.04.009. Epub 2020 Apr 29.

DOI:10.1016/j.ando.2020.04.009

PMID:32409004

Abstract

Amiodarone-induced thyrotoxicosis (AIT) are not uncommon endocrinopathies. Clinicians are sometimes faced with difficult diagnostic and therapeutic situations. The disease pathophysiology is partially understood, explaining the lack of predictive factors for occurrence. Different international recommendations for their management have been published: the most recent in 2018 by the European Thyroid Association (ETA) (Ross et al., 2016; Bartalena et al., 2018). The purpose of this paper is to present the essential concepts for their management and to review the literature since 2018.

摘要

胺碘酮相关性甲状腺毒症（AIT）是常见的内分泌疾病。临床医生有时会面临困难的诊断和治疗情况。该疾病的病理生理学部分被理解，这解释了缺乏对其发生的预测因素。不同的国际管理建议已经被发表：最近的是 2018 年由欧洲甲状腺协会（ETA）（Ross 等人，2016 年；Bartalena 等人，2018 年）。本文的目的是介绍其管理的基本概念，并回顾 2018 年以来的文献。